Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 50, Issue 1, 2017, Pages

  Johannson, Kerri A ^a,b   Vittinghoff, Eric ^c   Morisset, Julie ^d   Lee, Joyce S ^e   Balmes, John R ^c,f   Collard, Harold R ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DYSPNEA; FEASIBILITY STUDY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HOME MONITORING; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MALE; MEASUREMENT; MONITORING SPIROMETER; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; PROSPECTIVE STUDY; QUESTIONNAIRE; RELIABILITY; REPEAT PROCEDURE; SAMPLE SIZE; SIMULATION; SPIROMETRY; CALIFORNIA; COMPARATIVE STUDY; DEVICES; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; REGRESSION ANALYSIS; REPRODUCIBILITY; SELF CARE; TELEMEDICINE; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; CALIFORNIA; DYSPNEA; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MONITORING, PHYSIOLOGIC; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SELF CARE; SPIROMETRY; TELEMEDICINE; VITAL CAPACITY;

EID: 85026260747     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02406-2016     Document Type: Article

References (16)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
3. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
5. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
6. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis - FDA review of pirfenidone and nintedanib. N Engl J Med 2015; 372: 1189-1191.
7. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139: 609-616.
8. Vittinghoff EGD, Shiboski SC, McCulloch CE. Regression Methods in Biostatistics. New York, Springer, 2011.
9. Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: An effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 989-997.
10. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
11. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: The UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113: 619-624.
12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
13. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
14. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1769.
15. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
16. Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis: Considerations for future clinical trials. Eur Respir J 2015; 46: 243-249.